Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/2 Recruiting
428 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
CERTIS1
Phase 1/2 Recruiting
695 enrolled
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Phase 1/2 Recruiting
204 enrolled
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Phase 1/2 Recruiting
285 enrolled
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Phase 1/2 Recruiting
92 enrolled
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
Phase 1/2 Recruiting
55 enrolled
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Phase 1/2 Recruiting
100 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
250 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
Phase 1/2 Recruiting
22 enrolled
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Phase 1/2 Recruiting
180 enrolled
SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
120 enrolled
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/2 Recruiting
205 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
CYCAD-1
Phase 1/2 Recruiting
564 enrolled
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase 1/2 Recruiting
205 enrolled
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Phase 1/2 Recruiting
12 enrolled
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Phase 1/2 Recruiting
380 enrolled
AVZO-023-1001
Phase 1/2 Recruiting
380 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
Phase 1/2 Recruiting
74 enrolled
SIMONE
Phase 1/2 Recruiting
60 enrolled
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/2 Recruiting
460 enrolled
MK-1022-009
Phase 1/2 Recruiting
81 enrolled
ELUCIDATE
Phase 1/2 Recruiting
230 enrolled
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Phase 1/2 Recruiting
220 enrolled
ELECTRA
Phase 1/2 Recruiting
73 enrolled
ASPEN-09
Phase 1/2 Recruiting
80 enrolled
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Phase 1/2 Recruiting
100 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
Target-specific immunoPET Imaging of Breast Cancer
Phase 1/2 Recruiting
200 enrolled
Dauntless-1
Phase 1/2 Recruiting
61 enrolled
TAGNOT
Phase 1/2 Recruiting
58 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Phase 1/2 Recruiting
124 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Phase 1/2 Recruiting
300 enrolled
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
Phase 1/2 Recruiting
146 enrolled
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
100 enrolled
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Phase 1/2 Recruiting
196 enrolled